Zhongzhi Pharmaceutical Holdings Limited (HK:3737)
:3737
Want to see HK:3737 full AI Analyst Report?
3737 Stock Chart & Stats
HK$0.88
HK$0.04(4.04%)
At close: 4:00 PM EST
HK$0.88
HK$0.04(4.04%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$1.00
Previous CloseN/A
Volume157.00K
Average Volume (3M)412.77K
Market Cap
HK$677.60M
Enterprise ValueHK$622.08M
Total Cash (Recent Filing)HK$200.89M
Total Debt (Recent Filing)HK$227.02M
Price to Earnings (P/E)24.6
Beta0.05
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.43%
Share Statistics
EPS (TTM)0.01
Shares Outstanding863,600,000
10 Day Avg. Volume391,300
30 Day Avg. Volume412,766
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.38
Price to Sales (P/S)0.24
P/FCF Ratio5.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a stable equity base provide durable financial flexibility. With debt-to-equity near 0.21 the company can better withstand cyclical revenue pressure, fund targeted R&D or regulatory requirements, and pursue opportunistic investments without immediate refinancing stress.
Positive Free Cash FlowSustained positive free cash flow, despite a recent decline, shows the business can generate cash from operations to support capex and dividends. The demonstrated ability to rebound from past negative years suggests operational cash resilience and capacity to fund strategic priorities over months.
High Gross MarginA ~54% gross margin indicates strong product-level economics and pricing power in core lines. This structural margin buffer helps absorb SG&A or R&D spending, enabling the company to defend profitability and invest in pipeline or quality initiatives over a multi-month horizon.
Bears Say
Sharp Revenue DeclineA greater-than-20% revenue drop in the latest fiscal year signals weakening demand or lost market share. Prolonged top-line contraction undermines scale economics, pressures margins and makes funding consistent R&D, commercial expansion, or dividend distributions more difficult over the next several months.
Profitability CompressionSteep margin erosion—operating margin down to ~3.2% and net margin to ~1.0%—reduces internal capital generation and financial cushions. Persistently thin margins limit the firm's ability to invest, absorb shocks, or sustain dividends without structural operational improvements or cost rationalization.
Cash Flow VolatilityA near 50% YoY drop in free cash flow highlights volatile conversion from profits to cash. Such swings decrease predictability for capex and shareholder distributions, raise the need for working capital management, and constrain strategic initiatives until cash stability is restored.
Zhongzhi Pharmaceutical Holdings Limited News
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$1.00 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$677.60M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date is Aug 20, 2026 which is in 113 days.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.011.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Zhongzhi Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays a Annually dividend of HK$0.05 which represents an annual dividend yield of 9.43%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.176%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.77%
12-Months-Change
Fundamentals
Return on Equity
1.57%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---